Evidence map›Paper›PMID 38421677›Full record

ArticleJAMA oncology2024

Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence Variations.

Joanne Kotsopoulos, Jacek Gronwald, Tomasz Huzarski, Pål Møller, Tuya Pal, Jeanna M McCuaig, Christian F Singer, Beth Y Karlan, Amber Aeilts, Charis Eng and 15 more

Open access · greenAbstract read
In one paragraph

Article in JAMA oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
19.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 35 citations in OpenAlex.

  1. Trial
  2. Using Polygenic Risk Scores to Refine Risk and Outcomes in High-grade Serous Ovarian Cancer in Australia.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Contemporary risk assessment and risk-reducing strategies for tubo-ovarian cancer in women with BRCA pathogenic variants.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2026
    Review
  8. Observational
  9. Review
  10. Comparative Analysis ofJCO precision oncology · 2026
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Analysis ofInternational journal of molecular sciences · 2025
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 20 institutions in 6 countries.

Joanne KotsopoulosWomen's College Research Institute, University of Toronto, Toronto, Ontario, Canada.
Jacek GronwaldInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Tomasz HuzarskiInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Pål MøllerDepartment of Tumour Biology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Tuya PalVanderbilt-Ingram Cancer Center, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Jeanna M McCuaigPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Christian F SingerDepartment of Obstetrics and Gynecology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Beth Y KarlanDepartment of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles.
Amber AeiltsComprehensive Cancer Center, Division of Human Genetics, The Ohio State University Medical Center, Columbus.
Charis EngGenomic Medicine Institute and Center for Personalized Genetic Healthcare, Cleveland Clinic, Cleveland, Ohio.
Andrea EisenSunnybrook Odette Cancer Center, Department of Medical Oncology, University of Toronto, Toronto, Ontario, Canada.
Louise BordeleauDepartment of Oncology, Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada.
William D FoulkesMcGill Program in Cancer Genetics, Department of Oncology, McGill University, Montreal, Quebec, Canada.
Nadine TungCancer Risk and Prevention Program, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Fergus J CouchDivision of Experimental Pathology and Laboratory Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Robert FruscioClinic of Obstetrics and Gynecology, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Susan L NeuhausenDepartment of Population Sciences, Beckman Research Institute of City of Hope, Duarte, California.
Dana ZakalikGrosfeld Cancer Genetics Center, Beaumont Health, Oakland University William Beaumont School of Medicine, Royal Oak, Michigan.
Cezary CybulskiInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Kelly MetcalfeWomen's College Research Institute, University of Toronto, Toronto, Ontario, Canada.
Olufunmilayo I OlopadeDepartment of Medicine and Human Genetics, University of Chicago, Chicago, Illinois.
Ping SunWomen's College Research Institute, University of Toronto, Toronto, Ontario, Canada.
Jan LubinskiInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Steven A NarodWomen's College Research Institute, University of Toronto, Toronto, Ontario, Canada.
Hereditary Breast Cancer Clinical Study Group
Breast Cancer Research Foundation · USCancer Clinic · USInternational Hereditary Cancer Center · PLPublic Health Ontario · CAWomen's College Hospital · CABeaumont Health · USBeth Israel Deaconess Medical Center · USCity of Hope · USCleveland Clinic · USComprehensive Cancer Center Vienna · ATJuravinski Cancer Centre · CAMayo Clinic · USMcGill University · CAOslo University Hospital · NOPomeranian Medical University · PLSunnybrook Health Science Centre · CAThe Ohio State University Wexner Medical Center · USUniversity of California, Los Angeles · USUniversity of Chicago · USUniversity of Milano-Bicocca · IT

Funding

Resolving the cancer relevance of predisposition gene mutationsR35CA253187 · NCI · MAYO CLINIC ROCHESTER · PI Fergus Joseph Couch · 2020 to 2026
$5.8M
NCI NIH HHS R35 CA253187
6 · The paper itself

Abstract

Importance: Preventive bilateral salpingo-oophorectomy is offered to women at high risk of ovarian cancer who carry a pathogenic variant in BRCA1 or BRCA2; however, the association of oophorectomy with all-cause mortality has not been clearly defined. Objective: To evaluate the association between bilateral oophorectomy and all-cause mortality among women with a BRCA1 or BRCA2 sequence variation. Design, Setting, and Participants: In this international, longitudinal cohort study of women with BRCA sequence variations, information on bilateral oophorectomy was obtained via biennial questionnaire. Participants were women with a BRCA1 or BRCA2 sequence variation, no prior history of cancer, and at least 1 follow-up questionnaire completed. Women were followed up from age 35 to 75 years for incident cancers and deaths. Cox proportional hazards regression was used to estimate the hazard ratios (HRs) and 95% CIs for all-cause mortality associated with a bilateral oophorectomy (time dependent). Data analysis was performed from January 1 to June 1, 2023. Exposures: Self-reported bilateral oophorectomy (with or without salpingectomy). Main Outcomes and Measures: All-cause mortality, breast cancer-specific mortality, and ovarian cancer-specific mortality. Results: There were 4332 women (mean age, 42.6 years) enrolled in the cohort, of whom 2932 (67.8%) chose to undergo a preventive oophorectomy at a mean (range) age of 45.4 (23.0-77.0) years. After a mean follow-up of 9.0 years, 851 women had developed cancer and 228 had died; 57 died of ovarian or fallopian tube cancer, 58 died of breast cancer, 16 died of peritoneal cancer, and 97 died of other causes. The age-adjusted HR for all-cause mortality associated with oophorectomy was 0.32 (95% CI, 0.24-0.42; P < .001). The age-adjusted HR was 0.28 (95% CI, 0.20-0.38; P < .001) and 0.43 (95% CI, 0.22-0.90; P = .03) for women with BRCA1 and BRCA2 sequence variations, respectively. For women with BRCA1 sequence variations, the estimated cumulative all-cause mortality to age 75 years for women who had an oophorectomy at age 35 years was 25%, compared to 62% for women who did not have an oophorectomy. For women with BRCA2 sequence variations, the estimated cumulative all-cause mortality to age 75 years was 14% for women who had an oophorectomy at age 35 years compared to 28% for women who did not have an oophorectomy. Conclusions and Relevance: In this cohort study among women with a BRCA1 or BRCA2 sequence variation, oophorectomy was associated with a significant reduction in all-cause mortality.

Indexed as

Breast NeoplasmsOvarian NeoplasmsAdultAgedBRCA1 ProteinBRCA2 ProteinCohort StudiesFemaleHumansLongitudinal StudiesMiddle AgedMutationOvariectomyRisk ManagementBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, human

Identifiers

PMID38421677
PMCPMC10905374
OpenAlexW4392284556

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.